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Abstract
Background: The 10-repeat allele of a variable number tandem repeat (VNTR) polymorphism in
the 3'-untranslated region of the dopamine transporter gene (DAT1) has been associated with a
range of psychiatric phenotypes, most notably attention-deficit hyperactivity disorder. The
mechanism for this association is not yet understood, although several lines of evidence implicate
variation in gene expression. In this study we have characterised the genomic structure of the 9-
and 10-repeat VNTR alleles, and directly examined the role of the polymorphism in mediating gene
expression by measuring comparative in vitro cellular expression using a reporter-gene assay
system.
Results: Differences in the sequence of the 9- and 10- repeat alleles were confirmed but no
polymorphic differences were observed between individuals. There was no difference in expression
of reporter gene constructs containing the two alleles.
Conclusions: Our data suggests that this VNTR polymorphism may not have a direct effect on
DAT1 expression and that the associations observed with psychiatric phenotypes may be mediated
via linkage disequilibrium with other functional polymorphisms.
Background
The dopamine transporter (DAT) mediates uptake of
dopamine into presynaptic neurons, and is a major target
for various pharmacologically active stimulants such as
cocaine. Genetic association studies provide considerable
evidence that a variable number tandem repeat (VNTR)
polymorphism in the 3'-untranslated region (UTR) of the
dopamine transporter gene (DAT1) is associated with a
range of psychiatric phenotypes. In particular, the 10-
repeat allele of this polymorphism has been widely asso-
ciated with attention deficit hyperactivity disorder
(ADHD) (e.g. [1,2]), although there have been several
non-replications reported (e.g. [3,4]). The mechanism for
this association is not yet understood, although several
lines of evidence implicate variation in gene expression
[5]. The VNTR polymorphism consists of a 40 bp
sequence that most frequently occurs as 9 or 10 tandem
repeat units, although 3 through to 11 repeats are also
observed. Its location within the transcribed 3'-UTR is
interesting since these regions have been shown to play an
important role in the regulation of transcription effi-
ciency, mRNA stability or mRNA sub-cellular localization
[6].
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Several in vivo studies using single photon emission com-
puted tomography (SPECT) show an increased density of
DAT in ADHD probands compared to controls [7-10],
although such findings are not ubiquitous [11]. In addi-
tion, several studies suggest there may be an association
between VNTR genotype and DAT density [e.g. [12,13]].
Furthermore, methylphenidate, which is used as a treat-
ment for ADHD, has been shown to lower levels of DAT
in the brain [9]. Finally, the most thorough investigation
of methylphenidate response in relation to DAT1 geno-
type suggests that the 10-repeat allele is associated with a
positive response to the drug [14] as would be expected if
the density of the DAT, to which methylphenidate binds,
is increased in individuals with the 10-repeat allele. Two
smaller studies also report an effect of the DAT1 VNTR on
methylphenidate response, although they find poor
response is associated with the 10-repeat allele [15,16].
Previously, we measured DAT1 messenger RNA (mRNA)
levels in cerebellum, temporal lobe and lymphocytes and
observed that increased levels of DAT1 expression were
associated with the number of 10-repeat alleles [17].
These data suggested that the VNTR or another polymor-
phism in linkage disequilibrium (LD) with the VNTR is
involved in regulating expression of this gene.
A number of groups have investigated the functional role
of the DAT1 VNTR in vitro, although the results from these
studies are inconclusive. Michelhaugh et al demonstrated
that the human DAT1 9-repeat VNTR enhances transcrip-
tion in SN4741 cells, obtained from a mouse-embryonic
substantia nigra-derived cell line [18]. However, their
study did not compare the effect of the 10- versus the 9-
repeat. Furthermore, their constructs contained the repeat
region inserted upstream of the reporter gene promoter,
and not in the 3'UTR of the gene itself. Thus the position
of the repeat did not mirror that seen in the wild-type
DAT1 gene. It has been postulated that large repeat motifs
in the 3'UTR of genes may alter mRNA stability, but such
effects would not be detected in the research presented by
Michelhaugh et al. Furthermore, it has been shown that
the enhancing effect of sequence elements is largely deter-
mined by their relative location [19]. Fuke et al examined
the effect of the VNTR polymorphism on gene expression
using the luciferase reporter system in COS-7 cells [20].
They found that luciferase expression was significantly
higher in cells transfected with vectors containing the 10-
repeat allele compared to the 7-repeat or 9-repeat alleles.
However, they used a monkey cell-line that may not be
representative of endogenous human cells and did not
employ an internal transfection control for the numerous
forms of experimental variability that could affect their
data. Miller and Madras concluded that the 9-repeat allele
was correlated with increased expression in HEK-293 cells
compared with the 10-repeat, but that expression was fur-
ther mediated by a SNP also located in the 3'UTR of DAT1
[21]. Again, this study did not utilise the dual-luciferase
assay system and thus their data could be skewed by
experimental variability. Inoue-Murayama et al investi-
gated the functional effect of DAT1 VNTR alleles from sev-
eral primate species transfected into the human
neuroblastoma cell-line, SK-N-SH [22]. They found that
the VNTR sequences of nonhuman primates show higher
reporter-gene activity compared to human alleles, and a
general trend for longer VNTR alleles to reduce transcrip-
tion. Finally, Greenwood & Kelsoe found no effect on
transcription of the 9- and 10-repeat alleles in SN4741
cells, but found that introns 9, 12, and 14 may contain
enhancer elements capable of increasing expression ~2-
fold [23]. They conclude that it may be the particular com-
bination of polymorphisms in a haplotype across the gene
that ultimately effects DAT1 gene expression.
The aim of this study was to examine directly the role of
the VNTR polymorphism in mediating gene expression by
measuring comparative in vitro cellular expression imple-
menting a reporter-gene assay system in which the VNTR
has been inserted in an appropriate 3' configuration, and
using human cell-lines known to express DAT1. Analysis
was limited specifically to the VNTR sequence itself, so
that any functional effect detected could be attributed
solely to this candidate polymorphism. Another aim of
this study was to fully characterise the genomic structure
of the DAT1  VNTR. It is possible that any functional
effects of the VNTR are not mediated by repeat length, but
instead by variation in the actual sequence of the repeat
units. Recent work on the DRD4 exon III VNTR sequence
has demonstrated that there can be considerable variation
within the sequence of large VNTRs [24]. Such variation,
if present, could confound analyses of gene expression
and negate associations with disease based solely on
repeat length.
Results
Sequence analysis of the DAT1 VNTR
Differences were found between repeat motifs (the indi-
vidual repeat units making up the total VNTR), and nine
variants (labelled A-I) were detected in total (see Figure
1). Interestingly, although differences were found
between the orders of motifs in 9- and 10-repeat alleles,
they were identical for all examples of each allele size. The
order of motifs in the 10-repeat VNTRs was found to be A-
A-B-C-D-E-F-D-G-H, and the order in 9-repeat alleles was
found to be A-A-B-C-D-I-F-D-H. These sequences are iden-
tical to those reported by Fuke et al in a Japanese sample
[20]. Furthermore, aligning these sequences up against
those available on the NCBI database (accession numbers
NM_001044 and AF119117.1) also suggested a lack of
between-individual polymorphisms within the VNTR.
Interestingly, the 'I' motif (seen in the 9-repeat VNTR but
not the 10-repeat) appears to be a combination of the 'E'BMC Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2156/6/3
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and 'G' motifs (seen in the 10-repeat VNTR but not in the
9-repeat). The 'F' motif, which occurs in both the 9- and
10-repeat alleles, is also interesting in that it contains 45
base-pairs rather than 40. Furthermore, almost all the
between-motif variation occurs within the first (1–24 bp)
section of each sequence, before the location of the 5 bp
insertion in motif 'F'.
Luciferase activity from transiently transfected cells
Table 1 shows the luciferase transcriptional activity of the
seven transfected pGL3 plasmid constructs in SH-SY5Y
and HEK-293 cells. Plasmids containing the VNTR insert
produced slightly less transcriptional activity than the
original pGL3-promoter and pGL3-control plasmids in
both cell-lines, although this difference was not statisti-
cally different. No statistical difference in transcriptional
activity was detected between constructs containing the 9
or 10-repeat DAT1 VNTR sequence in either the SH-SY5Y
cells or the HEK-293 cells, although a slight decrease in
expression was noticed with increasing repeat length (no
insert > 9-repeat insert > 10-repeat insert). Some slight dif-
ferences were noted between the two cell lines: in both
SH-SY5Y cells and HEK-293 cells, the pGL3-basic plas-
mid, which contains neither promoter nor enhancer
sequences, generated the lowest transcriptional activity as
expected. In the SH-SY5Y cells, control plasmids
Alignment of the repeat motifs in the 9 and 10 repeat VNTR alleles Figure 1
Alignment of the repeat motifs in the 9 and 10 repeat VNTR alleles. Blue letters highlight deviations from the 'A' sequence 
motif. These sequences are identical to those observed in a Japanese population by Fuke et al [20].BMC Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2156/6/3
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containing both an enhancer and promoter showed sig-
nificantly higher levels of transcriptional activity than the
promoter plasmids, although this difference was not seen
in the HEK-293 cells.
Discussion
The aims of this study were twofold: first to characterise
the genomic structure of the DAT1 VNTR; and second to
investigate the effect of the 9- and 10-repeat VNTR alleles
on levels of transcription. It is possible that any effects,
both on behavioural phenotype or levels of DAT1 expres-
sion, commonly associated with the VNTR are due to pol-
ymorphisms  within  the repeat rather than the actual
length of the VNTR itself. This theory has often been pos-
tulated to explain cases of non-replication of association
studies with complex disorders. Recent work on the DRD4
exon III VNTR polymorphism has highlighted the exist-
ence of both within individual and between individual
variation in repeat motif sequence [24]. In other words
the 1st and 2nd repeat motifs within a certain length DRD4
VNTR allele may differ in sequence in a single individual,
but there is also variation within the 1st motif between dif-
ferent individuals. We sequenced the DAT1 VNTR in indi-
viduals homozygous for either the 9- or 10-repeat allele.
Differences were found between repeat motifs in both the
9- and 10-repeat alleles, and nine variants were detected
in total. Interestingly, although differences were found
between the 9- and 10-repeat alleles, the order of the
motifs was identical for all examples of each allele size.
Given that not one variation in these sequences was
observed in the 60 chromosomes sequenced, it can be
concluded that any between individual variations that do
occur are extremely rare and unlikely to be the cause of
common disorders such as ADHD.
Previously, Ueno et al screened the DAT1 3'UTR for novel
polymorphisms in a Japanese population, but only
detected a G>A SNP located upstream of the VNTR at posi-
tion 2319 [25]. Fuke et al have also sequenced the DAT1
VNTR in a small number of Japanese subjects with results
identical to those we describe [20]. Miller et al report a
SNP that abolishes a DraI restriction site, which they claim
to be within the 10-repeat allele [26]. Closer inspection of
their paper, however, shows that this polymorphism is
located outside of the repeat region and thus their conclu-
sion that they have found a 'novel variant of the 10-repeat
allele' is technically incorrect. It is possible, however, that
either this polymorphism or that discovered by Ueno et al
[25] may be the real risk variant, and associations reported
for the VNTR polymorphism may be a result of LD rela-
tionships with either of these SNPs.
The lack of between-individual variation in the sequence
of the DAT1 VNTR is perhaps surprising given the number
of polymorphisms seen in other large VNTRs (e.g. [24]).
VNTRs are often mutation hotspots with a high level of
genetic recombination due to misaligned repeat units that
can cause variations in sequence as well as length [27-29].
Furthermore, according to several estimates of SNP fre-
quency across the genome (e.g. [30]), the average total
repeat length of ~400 bp might be expected to contain at
least one SNP, especially as it is not located in a highly-
conserved coding-region of the gene. The fact that there
appears to be no between-individual variations within the
9- and 10-repeat VNTR sequences suggests that it may be
subjected to some form of selective pressure, and perhaps
have an important functional role. A clue to the impor-
tance of the DAT1  VNTR may come from its location
within the 3'UTR of the gene. Sequence motifs in the
3'UTR have been shown to have important roles in trans-
lation, mRNA stability, subcellular localization, and poly-
adenylation [6]. Alternatively, given that the between-
motif variations seen within the VNTR are ubiquitous, it is
possible that they are relatively ancient and have been
pushed towards fixation within the population via demo-
graphic and random genetic drift.
The second aim of this study was to examine in vitro pos-
sible functional consequences of the DAT1 VNTR poly-
morphism. We made constructs containing the 9- and 10-
repeat alleles of the DAT1 VNTR and the luciferase
reporter gene, and transiently transfected them into SH-
Table 1: Luciferase transcriptional activity of the DAT1 VNTR constructs in SH-SY5Y and HEK-293 cells.
pGL3 Construct Luciferase/Renilla ratio (95%CI)
SH-SY5Y HEK-293
pGL3-Basic 0.0033 (0.0026–0.0041) 0.1811 (0.1197–0.2424)
pGL3-Control 1.0407 (0.8464–1.2350) 1.7432 (1.1692–2.3172)
pGL3-Control-9rpt 0.7400 (0.6018–0.8781) 1.4963 (1.0416–1.951)
pGL3-Control-10rpt 0.5557 (0.4598–0.6515) 1.2098 (0.8637–1.5559)
pGL3-Promoter 0.1624 (0.0853–0.2396) 2.3461 (1.246–3.4462)
pGL3-Promoter-9rpt 0.1350 (0.1053–0.1646) 1.5967 (1.0963–2.0972)
pGL3-Promoter-10rpt 0.1172 (0.0929–0.1416) 1.2916 (0.925–1.6583)BMC Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2156/6/3
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SY5Y and HEK-293 cells. Constructs containing the VNTR
alleles gave slightly lower levels of luciferase activity com-
pared to vectors without the inserts. Although these differ-
ences were not statistically significant, they appear to go
against the conclusions of a previous study in which the
VNTR sequence acted as a strong enhancer of transcrip-
tion [18]. However, the trend of our results do agree with
data presented by Fuke et al who found that vectors con-
taining the VNTR polymorphism gave lower luciferase
expression levels compared to positive control vectors
having no VNTR inserted [20]. Furthermore, Greenwood
& Kelsoe found no evidence to suggest that the VNTR
sequence acts as a transcriptional enhancer [23]. The dis-
crepancies between these results may be explained by the
different methodological strategies employed. Michel-
haugh et al utilised GFP as a reporter gene [18], which
does not have the sensitivity or specificity associated with
the luciferase reporter system, and is generally used in
qualitative detection assays. Furthermore, they cloned the
VNTR sequence upstream of the SV40 promoter, in a loca-
tion not analogous to the 3'UTR location of the polymor-
phism in the DAT1 gene. The importance of the location
of regulatory elements has been well-documented [19]
and so it is possible that the enhancing effect reported by
Michelhaugh et al [18] is specific to the location of the
VNTR in their particular experimental design. Addition-
ally, it is possible that the VNTR polymorphism has an
important role in mediating processes such as mRNA sta-
bility – such effects will have been missed by Michelhaugh
et al, as their insert is not transcribed.
We found no significant differences in luciferase activity
between constructs containing the 9- or 10-repeat DAT1
VNTR alleles. Other transient expression studies that have
compared the VNTR alleles have provided mixed results.
Fuke et al found that luciferase expression was signifi-
cantly higher in cells transfected with vectors containing
the 10-repeat allele compared to the 7-repeat or 9-repeat
alleles [20]. Their study used a different cell-line, COS-7,
which is derived from African Green Monkey kidney.
Miller and Madras, on the other hand, concluded that the
9-repeat allele was correlated with increased expression in
HEK-293 cells, but that expression was further mediated
by a SNP also located in the 3'UTR of DAT1 [21]. Finally,
our data is in agreement with that of Greenwood & Kel-
soe, who also found no effect on transcription of the 9-
and 10-repeat alleles in SN4741 cells, but found that
introns 9, 12, and 14 may contain enhancer elements
capable of increasing expression ~2-fold [23].
Therefore, our data suggest that the VNTR polymorphism
itself may not be functional. Unlike the studies of Fuke et
al and Miller & Madras [20,21], our inserts contained no
flanking sequence and were restricted to specifically the
VNTR itself. There is considerable evidence that there is a
functional polymorphism in the vicinity of the 3'UTR of
the DAT1 gene. Genetic association studies with ADHD,
SPECT brain imaging studies, and correlations with levels
of DAT protein and DAT1 mRNA all suggest that a variant
associated with DAT1 expression is present in this region.
Given that in each of these associations, the VNTR has
been nominated as the causative polymorphism, it is
likely that the real risk variant is in strong LD with it. Ueno
et al and Miller et al both report novel SNPs located
within the 3'UTR and close to the VNTR [25,26]. It is pos-
sible that either of these SNPs, or another polymorphism
yet to be characterised, is mediating expression of DAT1
and is the real risk variant.
There are several obvious limitations to this study. First, it
is not known how well in vitro studies of gene expression
reflect patterns seen in vivo. Future work could employ
animal models to characterise more realistically the effect
of the VNTR on DAT1  expression. Second, while we
ensured that we used cell-lines that naturally express
DAT1, and inserted the VNTR into the correct 3'UTR loca-
tion of the luciferase reporter gene, our constructs could
have been improved by using a homologous DAT pro-
moter. Third, we only cloned a very small portion of the
DAT1 gene. Even though this was necessary to examine
functional effects specific to the VNTR, the fact that the
majority of the DAT1 gene was absent means that it is
likely that several cis-acting regulatory elements were not
present in the constructs and thus the observed expression
may not reflect the actual regulation of the gene. Finally
these studies have only analysed DAT1 gene expression in
the basal state, and complexities such as the induction of
expression by factors such as cellular signals would thus
be missed. Future work should focus on systematically
characterising the remainder of the 3'UTR to discover the
functional effects of other polymorphisms in this candi-
date region.
Conclusion
In this study we have characterised the genomic structure
of the 9- and 10-repeat DAT1 VNTR alleles, and directly
examined the role of the polymorphism in mediating
gene expression by measuring comparative in vitro cellular
expression using a reporter-gene assay system. No expres-
sion differences were observed between the 9- and 10-
repeat alleles suggesting that this polymorphism may not
have a direct effect on DAT1 function.
Methods
Sequence analysis of the DAT1 VNTR polymorphism
Before cloning the DAT1 VNTR and performing expres-
sion analyses it was imperative to characterise fully its
structure. If there was variation within the VNTR between
individuals who have repeats of the same length, then
these variants could confound expression analyses basedBMC Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2156/6/3
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simply upon length. Thirty individuals of predominantly
Caucasian ethnicity, homozygous for either the 9- or 10-
repeat allele of the VNTR, were selected for sequencing.
The VNTR region was amplified on an MJ PTC-225 ther-
mal cycler (MJ Research, Massachusetts, USA) using the
primers 5'- TGT GGT GTA GGG AAC GGC C-3' and 5'-
CAT TCG CAA ACA TAA AAA CTG TTG T-3' using a stand-
ard PCR protocol with a proofreading polymerase and an
annealing temperature of 58°C. PCR products were run
on a 2% agarose gel stained with ethidium bromide, and
then purified using the QIAquick Gel Extraction Kit (Qia-
gen, Crawley, UK). Purified fragments were sequenced
using an ABI BigDye Terminator (v3.0) Cycle Sequencing
kit (PE Applied Biosystems, Foster City, CA, USA) and
electrophoresed on an ABI 3100 Genetic Analyzer (PE
Applied Biosystems). Sequencing traces were analysed
using Sequencher software (Gene Codes Corporation,
Ann Arbor, MI, USA) and multiple samples aligned to aid
mutation detection.
Cloning the DAT1 VNTR into pGL3 gene expression 
vectors
The pGL3 expression vector family (Promega, UK) con-
tains an Xba  I restriction site (TCTAGA) immediately
downstream from the luciferase reporter gene, enabling
inserts to be cloned into the 3'UTR. Primers were designed
to directly flank the DAT1 VNTR and to both of these an
Xba I restriction site, along with three extra bases of DAT1
sequence, were added. The primer sequences used were:
5'-TGT TCT AGA TTG TGG TGT AGG GAA CGG C-3' and
5'-AGG TCT AGA AGA GTG TTG GTC TGC AGG CT-3'.
The aim of this project was to concentrate solely on the
functional significance of the VNTR, so flanking regions
around the VNTR were kept as small as possible. Using
these primers, the VNTR was amplified in individuals
homozygous for the 9- and 10-repeat alleles using stand-
ard PCR conditions with an annealing temperature of
55°C. The PCR products were isolated from a 2% agarose
gel as described above. The purified fragments were
cloned into pCRII TA cloning vectors (Invitrogen, UK),
which were then transformed into TOP10F E. Coli cells
(Invitrogen, UK) following the manufacturers protocol.
Colonies containing recombinant plasmids were identi-
fied using X-gal and IPTG. DNA from colonies containing
recombinant plasmids was prepared using a Qiagen Midi-
prep kit (Qiagen, UK), and the presence of insertions was
verified using Xba I restriction enzyme digestion and fur-
ther checked using direct plasmid sequencing. The Xba I
digested 9- and 10-repeat VNTR inserts were run on a 2%
agarose gel and purified as described above. The frag-
ments were cloned into pGL3-Control and pGL3-Pro-
moter vectors. The pGL3-Control vector contains both
SV40 promoter and enhancer sequences whereas the
pGL3-Promoter vector contains only an SV40 promoter.
Additionally the pGL3-Basic vector which lacks eukaryotic
promoter and enhancer elements was tested on its own
without any insert, for transcriptional activity and served
as a negative control. Five colonies from each of the four
cloning reactions (pGL3-Control-9rpt, pGL3-Promoter-
9rpt, pGL3-Control-10rpt, and pGL3-Promoter-10rpt)
were selected. Following plasmid DNA preparation, the
presence and orientation of the inserts was again verified
by Xba I digestion and fluorescent sequencing. New DNA
stocks for each of the 8 plasmids to be used in subsequent
transfection experiments (pGL3-Control, pGL3-Pro-
moter, pGL3-Basic, pRLSV40, pGL3-Control-9rpt, pGL3-
Promoter-9rpt, pGL3-Control-10rpt, and pGL3-Pro-
moter-10rpt) were prepared, and tested again by Xba I
digestion.
Cell culture, transient transfections, and luciferase assays
SH-SY5Y and HEK-293 cells were purchased from ATCC
(VA, USA). The SH-SY5Y cell line is a thrice-cloned sub-
line of the neuroblastoma cell line SK-N-SH. The HEK-
293 cell line is derived from human embryonic kidney. A
problem with many in vitro studies of gene expression
using reporter genes is that the cell-lines used do not nat-
urally express the gene of interest (i.e. DAT1). Before we
transfected our constructs into the SH-SY5Y and HEK-293
cell lines they were tested for DAT1  expression using
quantitative RT-PCR. Both cell lines were found to natu-
rally express DAT1 making them suitable for our experi-
ments (data not shown). In addition previous in vitro
studies have shown regulation of the DAT1 gene in both
the HEK-293 and SH-SY5Y cell lines [31,32], suggesting
endogenous expression of the gene in these cell types.
Both cell lines were cultured in 6-well tissue culture plates
containing Minimun essential medium Eagle (ATCC)
supplemented with 10% foetal bovine serum (Invitrogen,
UK). Cells were grown at 37°C in a humidified atmos-
phere containing 5% CO2. Transfection of the SH-SY5Y
cells was carried out using a calcium phosphate transfec-
tion kit (Invitrogen, UK). The two different transfection
methods used were found to be optimal for each line
respectively. The HEK-293 cell line was transiently trans-
fected using Lipofectamine 2000 (Invitrogen, UK). Trans-
fection efficiencies were normalised by the co-transfection
of the Renilla vector, pRL-SV40 (Promega, UK). Following
transfection, the cells were allowed to grow for 48 hours.
The cells were then washed and 500 µl cell lysis buffer
(Invitrogen, UK) was added to each well. The firefly luci-
ferase and Renilla luciferase assays were carried out using
the Dual-Luciferase Assay System (Promega, UK) follow-
ing the manufacturers protocol. All transfections were
done in triplicate, and repeated at least three times. All
comparisons between constructs were analysed by one-
way analysis of variance (ANOVA), followed by Tukey
post-hoc analysis for pairwise comparisons between spe-
cific plasmids.BMC Genetics 2005, 6:3 http://www.biomedcentral.com/1471-2156/6/3
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